UNSPSC 51371502: Tilidine

This classification denotes an opioid analgesic, narcotic, and cyclohexanecarboxylic acid with the molecular formula C17H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GY33N31E9Y, chemically known as 3-cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, trans-(+-)- but generally known as tilidine, which bears US NIH Compound Identifier 30131. European Medicines Agency schedules Tilidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11051MIG.

UNSPSC 51371502 Tilidine is a Commodity code that appears in state and local procurement records primarily for naloxone, safe drug deactivation systems, and broader generic multi-source pharmaceutical products rather than tilidine itself—reflecting how agencies tag acquisitions across opioid-response and pharmacy benefit management initiatives. State and local governments buying under this code are securing naloxone and harm-reduction supplies for community health programs, establishing direct-to-manufacturer pharmacy channels to manage costs, and procuring generic pharmaceuticals and over-the-counter products through cooperative purchasing vehicles. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple jurisdictions including Oregon).

Recent activity spans Florida, Texas, and the upper Midwest. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the contract includes a two-year initial term with optional one-year renewal and is potentially FEMA-funded. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor intelligence on direct-to-manufacturer prescription programs and self-insured pharmacy benefit arrangements outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline; pricing is weighted at 75 percent, and vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with products effective July 1, 2026.